Venus Medtech (Hangzhou) Inc. (VMTHF) Research

Venus Medtech (Hangzhou) Inc. specializes in the development and commercialization of transcatheter heart valve medical devices, serving markets in Mainland China and globally. Its product portfolio includes the VenusA-Valve, a transcatheter aortic valve replacement (TAVR) solution specifically designed for treating severe aortic stenosis, and the VenusP-Valve, a transcatheter pulmonary valve system addressing right ventricular outflow tract dysfunction. The company also provides V8/TAV8 balloon aortic valvuloplasty catheter systems. For critical protection during TAVR and other structural heart surgeries, Venus Medtech offers TriGUARD3, a cerebral embolic protection device engineered to mitigate brain damage risk and prevent cerebral embolism. Beyond its current offerings, the firm is actively developing next-generation TAVR candidates like VenusA-Plus and VenusA-Pilot, alongside transcatheter devices for mitral and tricuspid valve replacement. Its pipeline further includes the Liwen RF ablation system for hypertrophic cardiomyopathy and a renal denervation system aimed at managing hypertension. Founded in 2009, the company is headquartered in Hangzhou, People's Republic of China.

Open Venus Medtech (Hangzhou) Inc. (VMTHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.